Beta Bionics, Inc. (BBNX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$16.60

From 52W high−47.36%

Volume1.68M

Market cap$757.63M

P/E (TTM)—

P/S (TTM)6.4x

Div yield—

Key dataOct 19, 2026

Open

$16.60

From 52W high

−47.36%

Volume

1.68M

Market cap

$757.63M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.2x

P/E (TTM)

—

RSI (14)

41.0

MomentumView details →

1D Return

+3.00%

YTD Return

−43.81%

SummaryUpdated Jun 1, 2026

Beta Bionics, Inc. (NASDAQ:BBNX) is a commercial-stage medical device company founded in 2015 and based in Irvine, California. The company specializes in developing automated insulin delivery systems for people with diabetes, with its flagship product being the <b>iLet Bionic Pancreas</b>. Beta Bionics went public on January 30, 2025, representing a significant milestone for the company as it transitions from development to commercial expansion in the diabetes management market.

Ask drillr about Beta Bionics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−8.2x

EV/Sales

4.9x

P/S (TTM)

6.4x

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

58.31%

Net Margin

−61.32%

EBITDA Margin

−60.01%

ROE (TTM)

−28.46%

ROA (TTM)

−24.96%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

+52.54%

EPS YoY

+48.94%

FCF YoY

+1.04%

Revenue CAGR 3Y

+724.29%

EPS CAGR 3Y

−41.41%

EBITDA YoY

+1.51%

MomentumView details →

1D Return

+3.00%

YTD Return

−43.81%

1Y Return

−15.42%

RSI (14)

41.0

vs 50D SMA

−9.89%

vs 200D SMA

+13.35%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

8.88x

Quick Ratio

7.96x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

8.78%

Beats (12Q)

5/12

Next Q EPS Est

−$0.48

Avg Surprise (4Q)

17.89%

Rev Surprise

1.75%

Financials snapshotView financials →

Revenue (TTM)

119.01M

Net Income (TTM)

−72.97M

Op. CF (TTM)

−55.81M

Next earningsOct 27, 2026 →

Latest newsMore news →

HAGENS BERMAN SOBOL SHAPIRO LLP announced that November 3, 2026, was the deadline to seek appointment as lead plaintiff in the proposed investor lawsuit against Beta Bionics, Inc..3d ago

The DJS Law Group announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.15d ago

Similar companies

Brainaurora-b06681.HK 艾隆科技688329.SH Envista Holdings CorpNVST Nakamoto Inc.NAKA Concentra Group Holdings Parent, Inc.CON Park Dental Partners, Inc. Common StockPARK Find similar companies →

Latest newsMore news →

HAGENS BERMAN SOBOL SHAPIRO LLP announced that November 3, 2026, was the deadline to seek appointment as lead plaintiff in the proposed investor lawsuit against Beta Bionics, Inc..3d ago The DJS Law Group announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.15d ago Beta Bionics integrated Senseonics' Eversense 365 continuous glucose monitor into its iLet automated insulin delivery ecosystem.20d ago